Evidence map›Paper›PMID 18981773›Full record

Trial reportAIDS (London, England)2008

Determining an optimal testing strategy for infants at risk for mother-to-child transmission of HIV-1 during the late postnatal period.

Elizabeth Brown, Benjamin H Chi, Jennifer S Read, Taha E Taha, Usha Sharma, Irving F Hoffman, Cheryl Pikora, Robert Goldenberg, Susan A Fiscus

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in AIDS (London, England), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Evidence for optimal HIV screening and testing intervals in HIV-negative individuals from various risk groups: A systematic review.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2018
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Elizabeth BrownDepartment of Biostatistics, University of Washington and SCHARP, Fred Hutchison Cancer Research Center, Seattle, Washington, USA.
Benjamin H Chi
Jennifer S Read
Taha E Taha
Usha Sharma
Irving F Hoffman
Cheryl Pikora
Robert Goldenberg
Susan A Fiscus
National Institutes of Health · USCentre for Infectious Disease Research in Zambia · ZMDrexel University · USJohns Hopkins University · USUniversity of North Carolina at Chapel Hill · USUniversity of Washington · US

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
HIV PREVENTION TRIALS UNIT--MALAWIU01AI048005 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TAHA, TAHA E · 2000 to 2006
$37.6M
UAB-ZAMBIA-HAITI HIV PREVENTION TRIALS UNITU01AI047972 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI STRINGER, JEFFREY SAMUEL ALLEN · 2000 to 2006
$16.5M
HIV PREVENTION TRIALS UNITU01AI048006 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI FAWZI, WAFAIE W · 2000 to 2005
$14.3M
STATISTICAL &CLINICAL COORDINATING CENTER (SC)N01AI045200 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SELF, STEVEN G. · 1994 to 2000
$853k
INTNL.VACC.EFFICACY TRIALS MASTER CONTRACT (IMC)N01AI035173 · NIAID · FAMILY HEALTH INTERNATIONAL · PI CATES, WILLARD · 1993 to 2000
$0k
NIAID NIH HHS N01 AI035173NIAID NIH HHS N01 AI045200NIAID NIH HHS N01-AI-35173-117/412NIAID NIH HHS P30 AI050410NIAID NIH HHS U01 AI047972NIAID NIH HHS U01 AI048005NIAID NIH HHS U01 AI048006NIAID NIH HHS U01-AI-47972NIAID NIH HHS U01-AI-48005NIAID NIH HHS U01-AI-48006
6 · The paper itself

Abstract

objectivesTo determine the optimal time for a second HIV-1 nucleic acid amplification assay to detect late postnatal transmission of HIV-1 (first negative test at 4-8 weeks of age) in resource-limited settings.

designA longitudinal analysis of data from HIV Prevention Trial Network trial 024.

methodsChildren born to HIV-1-infected mothers enrolled in the HIV Prevention Trial Network trial 024 were tested for HIV-1 infection at six intervals within the first year of life. Mothers and infants received nevirapine prophylaxis. We estimated the probability of being alive and having a positive test in each interval after 4-8 weeks and at 30 days after weaning, conditional on having acquired HIV during the late postnatal period. The interval with the highest probability was taken to be the optimal visit interval.

resultsA total of 1609 infants from HIV Prevention Trial Network trial 024 had at least one HIV-1 diagnostic test and were included in the analysis. We found that testing at 1 month after weaning or 12 months of age (whichever comes first) identified 81% of those infected during the late postnatal period (after 4-8 weeks) through breastfeeding. In total, 93% (95% confidence interval 89, 98) of all infected infants would be detected if tests were performed at these two time points.

conclusionIn resource-limited settings, HIV-1 PCR testing at 4-8 weeks followed by a second test at 1 month after weaning or at 1 year of age (whichever comes first), led to the identification of the vast majority of HIV-1-infected infants.

Indexed as

AIDS SerodiagnosisAnti-HIV AgentsBreast FeedingDeveloping CountriesFemaleHIV-1HIV InfectionsHumansInfantInfant, NewbornLongitudinal StudiesMaleNevirapinePostnatal CarePregnancyPregnancy Complications, InfectiousAnti-HIV AgentsNevirapine

Identifiers

PMID18981773
PMCPMC2760032
OpenAlexW1998668803

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.